1![CABARET: Carboplatin and bevacizumab in recurrent glioblastoma study (Part 1) The CABARET trial is helping researchers answer an important health question. It is providing evidence for oncologists planning treatment for CABARET: Carboplatin and bevacizumab in recurrent glioblastoma study (Part 1) The CABARET trial is helping researchers answer an important health question. It is providing evidence for oncologists planning treatment for](https://www.pdfsearch.io/img/0859498ba6733f777f37c350f36ae4cf.jpg) | Add to Reading ListSource URL: www.ctc.usyd.edu.auLanguage: English - Date: 2016-03-21 02:14:55
|
---|
2![LABORATORY SCIENCES Preclinical Evaluation of the Novel Small-Molecule Integrin ␣51 Inhibitor JSM6427 in Monkey and Rabbit Models of Choroidal Neovascularization Grit Zahn, PhD; Dörte Vossmeyer, PhD; Roland Stragi LABORATORY SCIENCES Preclinical Evaluation of the Novel Small-Molecule Integrin ␣51 Inhibitor JSM6427 in Monkey and Rabbit Models of Choroidal Neovascularization Grit Zahn, PhD; Dörte Vossmeyer, PhD; Roland Stragi](https://www.pdfsearch.io/img/78bedb85a0e59abe9c9fb23d92908e3c.jpg) | Add to Reading ListSource URL: www.scleracorp.comLanguage: English - Date: 2013-08-13 00:02:52
|
---|
3![PRESTATIE- EN TARIEFBESCHIKKING ADD-ON RANIBIZUMAB Nummer Datum inwerkingtreding PRESTATIE- EN TARIEFBESCHIKKING ADD-ON RANIBIZUMAB Nummer Datum inwerkingtreding](https://www.pdfsearch.io/img/060100f353520f36bb2532f6752a3a77.jpg) | Add to Reading ListSource URL: www.nza.nlLanguage: Dutch - Date: 2015-03-05 04:45:12
|
---|
4![FOR IMMEDIATE RELEASE Quinton Oswald Appointed Chief Executive Officer of Neurotech Pharmaceuticals Seasoned Executive Brings Wealth of Experience to Ophthalmic Biotechnology Pioneer, Including Leadership of SARcode Bio FOR IMMEDIATE RELEASE Quinton Oswald Appointed Chief Executive Officer of Neurotech Pharmaceuticals Seasoned Executive Brings Wealth of Experience to Ophthalmic Biotechnology Pioneer, Including Leadership of SARcode Bio](https://www.pdfsearch.io/img/50155c253f1f4e39330e28d57ecbc646.jpg) | Add to Reading ListSource URL: www.neurotechusa.comLanguage: English - Date: 2015-02-04 14:45:03
|
---|
5![Novartis Pharmaceuticals Canada Inc. 385 Bouchard Blvd. Dorval, Quebec Canada H9S 1A9 www.novartis.ca Novartis Pharmaceuticals Canada Inc. 385 Bouchard Blvd. Dorval, Quebec Canada H9S 1A9 www.novartis.ca](https://www.pdfsearch.io/img/eb59f20a3c34192fd24c90fa220a0b00.jpg) | Add to Reading ListSource URL: www.novartis.caLanguage: English - Date: 2015-05-13 10:22:10
|
---|
6![FOR IMMEDIATE RELEASE Aerpio Therapeutics to Present at Needham Healthcare Conference Cincinnati, OH, April 7, 2013 – Aerpio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on advancing innovativ FOR IMMEDIATE RELEASE Aerpio Therapeutics to Present at Needham Healthcare Conference Cincinnati, OH, April 7, 2013 – Aerpio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on advancing innovativ](https://www.pdfsearch.io/img/810e260fa13cc8ceea8ac656f7b6afae.jpg) | Add to Reading ListSource URL: www.aerpio.comLanguage: English - Date: 2014-04-10 11:19:28
|
---|
7![FOR IMMEDIATE RELEASE Aerpio Therapeutics Initiates Phase 2 Study of Tie2 Activator AKB-9778 for the Treatment of Diabetic Macular Edema Cincinnati, OH, February 13, 2014 – Aerpio Therapeutics, Inc., a clinical-stage b FOR IMMEDIATE RELEASE Aerpio Therapeutics Initiates Phase 2 Study of Tie2 Activator AKB-9778 for the Treatment of Diabetic Macular Edema Cincinnati, OH, February 13, 2014 – Aerpio Therapeutics, Inc., a clinical-stage b](https://www.pdfsearch.io/img/6582c8d6e983948fb53c3972dab2f653.jpg) | Add to Reading ListSource URL: www.aerpio.comLanguage: English - Date: 2014-02-13 16:12:56
|
---|
8![PNAS PLUS Angiopoietin-like 4 is a potent angiogenic factor and a novel therapeutic target for patients with proliferative diabetic retinopathy Savalan Babapoor-Farrokhrana,1, Kathleen Jeea,1, Brooks Puchnera, Syed Juna PNAS PLUS Angiopoietin-like 4 is a potent angiogenic factor and a novel therapeutic target for patients with proliferative diabetic retinopathy Savalan Babapoor-Farrokhrana,1, Kathleen Jeea,1, Brooks Puchnera, Syed Juna](https://www.pdfsearch.io/img/798f13f6cbb9d7d1fd111a6157a69a3a.jpg) | Add to Reading ListSource URL: www.pnas.orgLanguage: English - Date: 2015-05-22 15:03:31
|
---|
9![FOR IMMEDIATE RELEASE Aerpio Therapeutics Closes $22M Financing --Proceeds Support Expanded Development Program for AKB-9778 and Advancement of HIF1 Activator into the Clinic-Cincinnati, OH, April 23, 2014 – Aerpio The FOR IMMEDIATE RELEASE Aerpio Therapeutics Closes $22M Financing --Proceeds Support Expanded Development Program for AKB-9778 and Advancement of HIF1 Activator into the Clinic-Cincinnati, OH, April 23, 2014 – Aerpio The](https://www.pdfsearch.io/img/c8678aa71fdb0a0eb7776ee59bf2f958.jpg) | Add to Reading ListSource URL: www.aerpio.comLanguage: English - Date: 2014-04-23 10:17:58
|
---|
10![Mother and daughter smile Mother and daughter smile](https://www.pdfsearch.io/img/26d2bf7ccaf93d24036a2e4d373eef62.jpg) | Add to Reading ListSource URL: www.maculardegeneration.com.auLanguage: English - Date: 2008-10-09 20:18:48
|
---|